Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

McKeage MJ, Kotasek D, Markman B, Hidalgo M, Millward MJ, Jameson MB, Harris DL, Stagg RJ, Kapoun AM, Xu L, Hughes BGM.

Target Oncol. 2018 Feb;13(1):89-98. doi: 10.1007/s11523-017-0543-0.


A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.

Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC.

Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. doi: 10.1158/1078-0432.CCR-17-2157. Epub 2017 Sep 27.


WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death.

Fischer MM, Cancilla B, Yeung VP, Cattaruzza F, Chartier C, Murriel CL, Cain J, Tam R, Cheng CY, Evans JW, O'Young G, Song X, Lewicki J, Kapoun AM, Gurney A, Yen WC, Hoey T.

Sci Adv. 2017 Jun 21;3(6):e1700090. doi: 10.1126/sciadv.1700090. eCollection 2017 Jun.


Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.

Lim JS, Ibaseta A, Fischer MM, Cancilla B, O'Young G, Cristea S, Luca VC, Yang D, Jahchan NS, Hamard C, Antoine M, Wislez M, Kong C, Cain J, Liu YW, Kapoun AM, Garcia KC, Hoey T, Murriel CL, Sage J.

Nature. 2017 May 18;545(7654):360-364. doi: 10.1038/nature22323. Epub 2017 May 10.


Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV.

J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21.


Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

Chartier C, Raval J, Axelrod F, Bond C, Cain J, Dee-Hoskins C, Ma S, Fischer MM, Shah J, Wei J, Ji M, Lam A, Stroud M, Yen WC, Yeung P, Cancilla B, O'Young G, Wang M, Kapoun AM, Lewicki J, Hoey T, Gurney A.

Cancer Res. 2016 Feb 1;76(3):713-23. doi: 10.1158/0008-5472.CAN-15-0561. Epub 2015 Dec 30.


Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.

Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, Henner WR, Meisner R, Sato A, Shah J, Tang T, Wallace B, Wang M, Zhang C, Kapoun AM, Lewicki J, Gurney A, Hoey T.

Clin Cancer Res. 2015 May 1;21(9):2084-95. doi: 10.1158/1078-0432.CCR-14-2808.


A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.

Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, Kapoun AM, Xu L, Dupont J, Sikic B.

Clin Cancer Res. 2014 Dec 15;20(24):6295-303. doi: 10.1158/1078-0432.CCR-14-1373. Epub 2014 Oct 16.


Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.

Yen WC, Fischer MM, Hynes M, Wu J, Kim E, Beviglia L, Yeung VP, Song X, Kapoun AM, Lewicki J, Gurney A, Simeone DM, Hoey T.

Clin Cancer Res. 2012 Oct 1;18(19):5374-86. doi: 10.1158/1078-0432.CCR-12-0736. Epub 2012 Sep 5.


Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.

Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ.

Breast Cancer Res Treat. 2012 Oct;135(3):913-22. doi: 10.1007/s10549-012-2226-y. Epub 2012 Sep 2.


Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.

Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, Mitra S, Park IK, Pickell K, Sato A, Satyal S, Stroud M, Tran H, Yen WC, Lewicki J, Hoey T.

Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. doi: 10.1073/pnas.1120068109. Epub 2012 Jul 2.


Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.

Cancer Res. 2011 Mar 1;71(5):1520-5. doi: 10.1158/0008-5472.CAN-10-2817. Epub 2010 Dec 30.


Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma A.

Blood. 2008 Oct 15;112(8):3434-43. doi: 10.1182/blood-2008-02-139824. Epub 2008 May 12.


Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, Wong DH, Higgins LS.

Anticancer Res. 2007 Nov-Dec;27(6B):4149-57. Erratum in: Anticancer Res. 2008 Jan-Feb;28(1b):567, 4152-3.


Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.

Koppelman B, Webb HK, Medicherla S, Almirez R, Feng Y, Chavez JC, Mao CP, Nguyen A, Liu YW, Kapoun AM, Muiru G, Huang YA, Dugar S, Mavunkel BJ, Lim DW, Chakravarty S, Luedtke G, Protter AA, Higgins LS.

Pharmacology. 2008;81(3):204-20. doi: 10.1159/000112865. Epub 2008 Jan 7.


p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation.

Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS.

J Pharmacol Exp Ther. 2008 Mar;324(3):921-9. Epub 2007 Dec 4.


Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.

Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS.

Hypertension. 2007 Oct;50(4):686-92. Epub 2007 Aug 27.


Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH.

Neuro Oncol. 2007 Jul;9(3):259-70. Epub 2007 May 23. Erratum in: Neuro Oncol. 2007 Oct;9(4):465.


B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells.

Liang F, Kapoun AM, Lam A, Damm DL, Quan D, O'Connell M, Protter AA.

Endocrinology. 2007 Aug;148(8):3722-9. Epub 2007 May 3.


Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.

Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, O'Young G, Quon D, Henson M, Damm DL, Muiru GT, Murphy A, Higgins LS, Chakravarty S, Wong DH.

Mol Pharmacol. 2007 Jul;72(1):152-61. Epub 2007 Mar 30.


Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS.

Mol Pharmacol. 2006 Aug;70(2):518-31. Epub 2006 May 17.


Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.


Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.

Exp Cell Res. 2006 Jun 10;312(10):1909-23. Epub 2006 Apr 4.


A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.

Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA.

J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. Epub 2006 Apr 5.


p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Lim MY, Wang H, Kapoun AM, O'connell M, O'Young G, Brauer HA, Luedtke GR, Chakravarty S, Dugar S, Schreiner GS, Protter AA, Higgins LS.

J Mol Cell Cardiol. 2004 Dec;37(6):1111-4.


Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J.

Am J Respir Crit Care Med. 2005 Apr 15;171(8):889-98. Epub 2004 Nov 24.


p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats.

Li Z, Tran TT, Ma JY, O'Young G, Kapoun AM, Chakravarty S, Dugar S, Schreiner G, Protter AA.

J Cardiovasc Pharmacol. 2004 Oct;44(4):486-92.


B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.

Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA.

Circ Res. 2004 Mar 5;94(4):453-61. Epub 2004 Jan 15.


Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis.

Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, Nikolic-Paterson DJ.

J Am Soc Nephrol. 2003 Feb;14(2):338-51.


Altered patterns of gene expression in response to myocardial infarction.

Stanton LW, Garrard LJ, Damm D, Garrick BL, Lam A, Kapoun AM, Zheng Q, Protter AA, Schreiner GF, White RT.

Circ Res. 2000 May 12;86(9):939-45.


Molecular control of the induction of alcohol dehydrogenase by ethanol in Drosophila melanogaster larvae.

Kapoun AM, Geer BW, Heinstra PW, Corbin V, McKechnie SW.

Genetics. 1990 Apr;124(4):881-8. Erratum in: Genetics 1990 Oct;126(2):477.

Supplemental Content

Loading ...
Support Center